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Phospholemman (PLM) is a 72-residue bitopic 
cardiac transmembrane protein, which acts as 
a modulator of the Na+/K+-ATPase, the 
Na+/Ca2+ exchanger , and possibly forms 
taurine channels in non-heart tissue. This work 
presents a high-resolution structural model 
obtained from a combination of site-specific 
infrared spectroscopy and experimentally 
constrained high-throughput molecular 
dynamics (MD) simulations. Altogether 37 
experimental constraints including 9 long-range 
orientational constraints have been used during 
MD simulations in an explicit lipid 
bilayer/water system.  The resulting tetrameric 
α-helical bundle has an average helix tilt of 7.3° 
and a crossing angle close to 0°. It does not 
reveal a hydrophilic pore but instead strong 
interactions between various residues occlude 
any pore. The helix-helix packing is unusal with 
Gly19 and Gly20 pointing to the outside of the 
helical bundle facilitating potential interaction 
with other transmembrane proteins, thus 
providing a structural basis for the modulatory 
effect of PLM on the Na+/K+-ATPase. A two-
stage model of interaction between PLM and 
the Na+/K+-ATPase is discussed involving PLM-
ATPase interaction and subsequent formation 
of an unstable PLM trimer, which readily 
interacts with surrounding ATPase molecules.  
Further unconstrained MD simulations 
identified other packing models of PLM, one of 
which could potentially undergo a confor-
mational transition to an open pore. 
 
Human phospholemman (PLM) is a member of a 
family of single-span transmembrane proteins 
characterised by the invariant extracellular motif 
FXYD (1) and is also known as FXYD1. It is 
found in liver, skeletal muscle and most 
abundantly in the cardiac sarcolemma (2). Over 
recent years conclusive experimental evidence has 
been presented that PLM acts as a tissue specific 
modulator of the Na+/K+-ATPase similar to the 
other members of the FXYD family, each of 
which is prevalent in a different tissue, 
summarised in several recent reviews (3,4). The 
Na+/K+-ATPase consists of a catalytic α-subunit 
with 10 transmembrane segments and a β-subunit 
involved in membrane insertion and as a 
modulator of transport properties (5). In particular 
cross-linking and modelling studies revealed the 
direct interaction between the Na+/K+-ATPase α-
subunit and members of the FXYD family (γ and 
CHIF), which involves the binding of a single 
transmembrane domain into a groove formed by 
M2, M6 and M9 transmembrane helices of the 
Na+/K+-ATPase (6,7). PLM appears to be a major 
control point in the function of heart cells, 
although its specific physiological role is unclear, 
complicated by the possibility that its regulatory 
effect on the Na+/K+-ATPase may depend on the 
phosphorylation state of PLM (8) as well as other 
less well established functional roles, e.g. 
interaction with the Na/Ca2+ exchanger (9,10) or 
independent channel formation. PLM knockout 
mice expressed a complex response including 
increased cardiac mass, larger cardiomyocytes and 
ejection fractions in the absence of hypertension, 
while the overall Na+/K+-ATPase activity was 
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reduced by 50% (11). There is growing evidence 
that PLM regulates the activity of Na/Ca2+ 
exchanger 1 (NCX1) from heterologous 
expression studies of PLM and NCX1 in HEK239 
cells (10), overexpression of PLM in rat 
cardiomyocytes (12,13) using different approaches 
to measure NCX1 activity. It appears that 
phosphorylation of PLM abolishes its inhibitory 
effect on the Na+/K+-ATPase (14,15), while the 
phosphorylated form of PLM inhibits NCX1 
(9,12). 
Electrical measurements of PLM in artificial lipid 
bilayers and oocytes showed that PLM facilitates 
the membrane flux of ions (16) and taurine 
transport (17), which leads to the possibility that 
PLM has a function in the regulation of cell 
volume either as a modulator of a swelling-
activated signal transduction pathway or directly 
facilitating osmolyte influx in non-cardiac tissues 
(18). 
The three-dimensional structure of PLM is not 
known, but on the basis of hydropathy analysis of 
the amino acid sequence a transmembrane domain 
from residue 18 to 37 has been predicted (2) and 
confirmed later by attenuated total reflection 
(ATR) FTIR spectroscopy (19). The C-terminus is 
located intracellulary, resistant to protease 
digestion, while the N-terminus is located 
extracellulary as shown by antibody labelling (20). 
A PLM peptide of residues 12 to 39 comprising 
the transmembrane domain forms α-helical 
tetramers in lipid bilayers, which are tilted by less 
than 17° against the membrane normal (19). Here 
we present a detailed three-dimensional structure 
of the tetrameric transmembrane domain based on 
site-specific infrared dichroism (SSID) (21,22) 
combined with a recently developed 
conformational search based on experimentally 
constrained high-throughput molecular dynamics 
(MD) simulations in an explicit lipid bilayer. 
(23,24). 
 
EXPERIMENTAL PROCEDURES 
 
Preparation of Labelled Peptides – 1-13C amino 
acids were obtained from Cambridge Isotope 
Laboratories (Cambridge, MA) and further 
labelled by reaction with H218O catalysed by 
gaseous hydrochloric acid (25,26). The labelled 
amino acids were then Fmoc protected by a 
standard procedure using Fmoc-N-succinimyl-
carbonate (27). 
Ten peptides of the transmembrane domain 
sequence of PLM (residues 12-39 
DYQSLQIGGLVIAGILFILGILIVLSRR) were 
obtained from Keck Laboratories (Yale University, 
USA). Each peptide contains one 1-13C=18O 
labelled residue in the positions shown in boldface. 
 
Preparation of Proteoliposomes – Peptides were 
mixed with dimyristoylphosphocholine (DMPC) 
lipids in hexafluoroisopropanol (HFIP) at a ratio 
of approx. 1:30 (w/w). Liposomes were then made 
by complete evaporation of the HFIP and addition 
of water to a lipid concentration of 10 mg/ml. The 
lipid suspension was then sonicated and subjected 
to a freeze-thaw cycle three times. 
 
Infrared Spectroscopy – The liposome suspensions 
were deposited onto a trapezoidal Germanium 
refraction element (50 mm x 2 mm x 20 mm) and 
bulk water was removed under a stream of 
nitrogen, forming a thick film compared to the 
penetration depth of the IR light on the element. 
Attenuated total reflection (ATR) FTIR spectra 
were obtained using a Bruker Tensor FTIR-
Spectrometer (Bruker Optics, Coventry, UK) with 
a high sensitivity liquid nitrogen cooled MCT/A 
detector. One spectrum was calculated from the 
average of 1000 interferograms at a resolution of 
2cm-1 per data point in the 4000 cm-1 to 1000 cm-1 
range of the electromagnetic spectrum In each case 
the spectra was recorded at parallel and 
perpendicular polarisation to the plane of 
incidence and the dichroic ratio was calculated as 
the ratio between the integrated absorption of 
parallel and perpendicular polarised light for the 
amide I absorption band centred at a wavenumber 
of 1658 cm-1 and for the 13C=18O absorption band 
centred at 1594 cm-1. For each labelled peptide, at 
least three independent measurements were taken. 
 
Data Analysis – The spectra were analysed 
according to the theory of site-specific infrared 
dichroism (SSID) presented elsewhere (22,28,29). 
Briefly, the dichroic ratios of the amide I 
absorption band and the absorption band of the 
label for two peptides with labels in position 1 and 
2 were analysed together in order to obtain the 
local helix tilt angle β and the rotational pitch 
angle ω for the label in position 1. Another peptide 
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with a label in position 3 was analysed in order to 
give the orientational parameters for position 2 
and so on. In that way the following pairs of labels 
were analysed G20/L21, L21/V22, V22/I23, 
I23/G25, G25/I26, I26/L27, L27/G31, G31/I32, 
I32/L33. 
The angle between the C=O bond and the z-axis θz 
used as orientational constraint was calculated as 
follows: 
)17cos(sinsincoscoscos °+−= ωβαβαθz wit
h α = 180° - 38° = 142° denoting the angle 
between the transition dipole moment and the 
molecular director given by Marsh et al. (30). All 
calculations were carried out using the 
Mathematica 5 software (Wolfram Research, 
Champaign, IL). 
 
High Throughput Molecular Dynamics 
Conformational Searching – The conformational 
search of PLM tetrameric helical bundles were 
carried out as described elsewhere for a dimeric 
system (23,24). Briefly, α-helical bundles were 
generated by symmetrically rotating the helices in 
10° increments in order to produce an array of 
starting structures for MD simulation. Both left 
and right-handed crossing bundles (crossing angle 
of ±25°) were generated giving 72 different 
orientations, with each being simulated at four 
different initial random velocities resulting in a 
total of 288 starting structures. Each structure was 
subjected to 200 ps MD simulation using the 
GROMACS software (31) in a DMPC 
bilayer/water system containing 128 DMPC 
molecules and 3655 water molecules. The initial 
coordinates of the DMPC bilayer were obtained 
from Gurtovenko et al. (32). Constraints were 
placed on each α-helical bundle, the angle between 
the z-axis and the C=O bond of the label was 
constrained to the derived value from SSID. The 
local tilt angle was also constrained by defining 
the angle between the z-axis and a vector between 
the Cα atoms of the residue in question and a 
residue seven positions along in the helix. Also, as 
the peptide is known to be α-helical (as detected 
from IR), the distances between hydrogen bonding 
pairs of amine hydrogens and carbonyl oxygens 
were constrained between 1.6 nm and 2.3 nm, a 
harmonic potential was applied outside these 
boundaries. All constraints were added to the 
GROMACS forcefield with a force constant of 
5000 kJ mol-1. For the unconstrained search the 
same procedure was followed without applying 
any constraints. All MD simulations were 
performed in parallel on an 8 node dual 2.66 GHz 
Xeon processor cluster (Streamline Computing, 
Warwick, UK). 
 
Clustering of Structures – Cα root-mean-square-
deviation (RMSD) comparisons were made 
between all resulting structures from the search. 
Structures were then clustered according to their 
RMSD values. The adopted criteria for structure 
clustering were that of a maximum RMSD value 
of 2 Å between two structures. For a cluster to be 
created, a minimum of five structures possessing 
RMSD values within this limit was required. 
The structures contributing to this cluster were 
then used to create an average structure, which 
was subjected to experimentally constrained MD 
simulation for 2ns in a lipid bilayer followed by 
energy minimisation. The coordinates of the 
experimentally constrained PLM model  have been 
deposited with the RCSB Protein Data Bank, PDB 
ID 2j1i. 
 
  
RESULTS 
 
ATR Infrared Spectroscopy – Altogether ten PLM 
transmembrane peptides containing residues 12 to 
39 with 13C=18O labelled residues in the positions 
indicated in figure 1 have been reconstituted in 
dimiristoyl-phosphatidylcholine vesicles and 
analysed by polarised attenuated total reflection 
infrared spectroscopy. The symmetric amide I 
absorption band centred at approx 1658 cm-1 
revealed that in all cases the peptide adopted a 
predominantly α-helical conformation (33) 
confirming earlier observations (19). The 
absorption band of the labelled sites centred at 
1594 cm-1 showed that the label is also in an α-
helical environment (26). In some cases a shoulder 
existed at 1618 cm-1 (figure 1) representing the 
absorption of a residue with 13C=16O carbonyl 
bond, which is caused by incomplete labelling of 
the amino acid with H218O prior to peptide 
synthesis. However, in all cases the 13C=18O bond 
was of sufficient intensity for analysis. 
The dichroic ratio of the amide I peak varied from 
2.5 to 4.2, depending on sample order; whilst the 
dichroic ratio of the 13C=18O peak varied from 2.1 
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to 5.8, depending on position and sample order. 
The dichroic ratio of the label is in all cases 
different from the dichroic ratio of the unlabelled 
amide I peak, which is indicative of 
oligomerisation. A label in a monomeric helix 
would adopt an average dichroic ratio similar to 
the unlabelled residues due to rotational symmetry 
with respect to the membrane normal. The local 
helix tilt shows variation between (3±4)° and 
(10±4)°, while the change in rotational pitch angle 
ω is in the region of 100° for successive residues 
in accordance with α-helical geometry (table 1). 
The angle between the C=O bond and the z-axis, 
calculated from ω andβ, are used as experimental 
constraints for the MD simulation. 
 
Constrained High-Throughput MD – At each stage 
of the MD simulation and energy minimisation a 
total of 37 experimental constraints have been 
applied composed of nine orientational constraints 
obtained from SSID of ten labelled peptides (table 
1),  in order to set the local helix tilt and distance 
constraints between the carbonyl oxygen of 
residue n and the amide hydrogen of residue n+4 
in order to maintain the experimentally determined 
α-helical geometry, although unconstrained 
simulations of helices in lipid bilayers have shown 
that α-helices are retained even after long term 
MD simulations (23,24). Following the MD 
simulation of 72 different starting structures each 
at four different random initial atom velocities 
(288 simulations), a cluster analysis provided six 
structures (figure 2). Of these, structure 6 showed 
the closest agreement with the rotational pitch 
angles obtained from SSID experiments (table 2), 
even though structure 6 was of slightly higher 
energy than other structures. It is generally 
accepted that similarity to experimental studies is 
a far more accurate determinant than force-field 
energy. 
Structure 6 is a right-handed α-helical bundle with 
a crossing angle close to 0°, whilst local helix tilt 
angles derived from the IR data vary from 2.5° to 
10.1° depending on the site in question, resulting 
in an average tilt angle of 7.3°. This is in 
accordance with previous conventional ATR-FTIR 
experiments, which indicated an average tilt angle 
between 0° and 17° (19), if the sample order is not 
taken into account. 
In the transmembrane region, the residues in the 
helices adopt α-helix geometry throughout, but 
close to the termini some are locally distorted. 
This region does not possess any constraints and 
therefore this effect is most likely due to the 
greater freedom of movement these residues will 
have. The centre of structure 6 is occluded by 
interactions between residues Tyr27, Gln31, 
Leu35, Phe42, Ile46, Leu50 and Arg53. 
 
Unconstrained High-Throughput MD – In order to 
explore the range of all possible packing models of 
PLM in lipid bilayers, we performed a high-
throughput MD search without any constraints 
applied. In this simulation we found 9 clusters of 
structures and calculated an average structure for 
each cluster (fig. 5A). The starting structure for the 
helix rotation φ = 0° is the same as shown in fig. 
2B. Each cluster average structure reveals a well 
packed α-helical tetramer. In order to find a model, 
which would support the experiments of PLM ion 
channel activity, we analysed visually each 
structure for the possibility of the formation of a 
hydrophilic pathway through the centre of the 
tetramer. For most structures the centre of the 
tetramer is completely occluded by interactions 
between several residues, but in structure number 
4 only the side-chains ofVal34 and Tyr27 occlude 
the centre of the structure as shown in fig. 5B, 
while other side-chains are either pointing to the 
outside or are involved in close packing 
interaction at the helix-helix interface. Tyr27 is 
located in the water phase at the N-terminal end of 
the peptide and shows a high conformational 
flexibility in MD simulations, thus would not 
contribute significantly to occlusion of the pore, 
while Val34 is located in the transmembrane 
domain. Structure number 4 has the lowest energy 
of all unconstrained packing models of -1299 kJ, 
while the next lowest energy structure is structure 
3 with -1253 kJ.  
 
DISCUSSION 
Constrained High-throughput MD simulation – 
The conformational search combining MD 
simulations in a realistic environment with long-
range orientational constraints allowed us to obtain 
an experimentally defined structural model of the 
PLM tetrameric transmembrane domain with 
atomic detail.  
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However, a comparison of the rotational pitch 
angles between the experiment and the best model 
structure 6 reveals some deviations (table 2). This 
is caused on the one hand by the interplay between 
the experimental constraints and the tendency of 
the structure to adopt an energy minimum in the 
“imperfect” computational forcefield, which also 
takes into account side chain packing and protein-
lipid interaction for which we have no 
experimental data. On the other hand, the 
rotational pitch angle for a residue is a derived 
parameter assuming ideal α-helix geometry, which 
is not the case for PLM and other helices, thus 
calculation of this angle leads to deviations, while 
the angles between the C=O bond and the z-axis 
used as actual constraints in the simulation were 
matched precisely (data not shown). However, as 
the rotational pitch angle of a residue defines the 
interaction side of helices in a bundle, 
comparisons based on this angle have been proven 
most reliable even allowing the determination of 
the preferred oligomerisation state (34). 
 
PLM as Na+/K+-ATPase regulator – PLM has 
three regions of its transmembrane sequence 
conserved in human, canine, mouse and rat 
versions of the protein (1,35,36), residues 18-21 
(IGGL), residues 23-34 (IAGILFILGILI) and 
residues 36-37 (LS). Val22 is mutated to Thr in 
mouse and rat, and to Ile in canine species whilst 
Val35 is maintained in canine and mutated to Ile 
in mouse and rat. In our model the residues Ile18, 
Gly19 and Gly20 all point outwards toward the 
lipid environment and therefore do not form inter-
helical interactions, however the Leu21 residues 
are in the interior of the α-helical complex and 
appear to pack uniformly. The Leu36 and Ser37 
residues protrude outwards into the surrounding 
environment, however this region is in the water 
phase. In the 23-34 residue region; the Gly25, 
Phe28 and Ile32 residues form the inter-helical 
binding motif. Perhaps surprisingly, only one 
glycine residue packs in the interior of the 
complex while all others point outwards into the 
lipid environment. One possible explanation is that 
this arrangement allows PLM to interact with 
other transmembrane proteins e.g. the Na+/K+-
ATPase. Of the non-conserved residues, Val22 
and Val35 are in the interfacial region. 
In our PLM model, the Phe28 residues reside in 
the interior of the complex. Interestingly, previous 
experimental cross-linking studies of the related γ-
subunit identified a Phe residue that was in close 
proximity to neighbouring helices of the Na+/K+-
ATPase (6). Also Leu42 and Ile43 were identified 
from modelling studies (in the γ-subunit) to be 
close to other helices in this complex. These 
residues are conserved in PLM (as Leu33 and 
Ile34). In the PLM model presented here, both 
these residues protrude into the lipid environment. 
The biological consequences of these findings are 
that even in its oligomeric form PLM would be 
able to interact with the Na+/K+-ATPase, either by 
stable interaction of the whole PLM tetramer or by 
forming an intermediate complex from which a 
PLM monomer is abstracted leaving behind a 
trimer.  
 
Two-stage model of PLM-Na+/K+-ATPase 
interaction – Based on the structure obtained in 
this report and earlier investigations (19) we 
present a model of interaction between PLM and 
the Na+/K+-ATPase that involves a transient 
intermediate complex between the PLM tetramer 
and the and the Na+/K+-ATPase. This interaction 
provides the energy to strip out a subunit of the 
tetramer in a slow process followed by a fast step 
of association between the remaining PLM trimer 
and surrounding Na+/K+-ATPase molecules (figure 
4). The molecular surface of the PLM tetramer 
presents a hole at the positions Gly19, Gly20 
(figure 4A), which would enable PLM to pack 
closely against other transmembrane helices in this 
region. On the other hand Leu33 and Ile34 are 
pointing to the outside of the PLM tetramer and 
those residues are believed to be in close 
proximity to the Na+/K+-ATPase transmembrane 
helices (in the related γ-subunit (6)). Thus we 
postulate that the PLM tetramer is able to interact 
with the Na+/K+-ATPase at a groove formed by 
M2, M6 and M9 transmembrane helices (figure 
4B). Also the Phe28 was identified by cross 
linking experiments (in the related γ-subunit) to be 
in close proximity to the Na+/K+-ATPase, while 
our PLM tetramer model would not allow the 
formation of cross links to other residues of 
interacting transmembrane helices. Phe28 in our 
model is buried in the interior of the helical bundle 
(figure 3C). Thus we must postulate either a 
conformational change or the dissociation of a 
PLM trimer from the ATPase/PLM tetramer 
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complex. The latter possibility is supported by the 
experimental evidence that a PLM monomer co-
immunoprecipitates with the ATPase (10). 
Oligomerisation studies did not show the existence 
of a PLM trimer (19), thus it would be unstable 
and readily interact in a second fast stage with 
other Na+/K+-ATPase molecules in the lipid 
membrane (figure 4B). The biological advantage 
of our model is a very responsive mode of control 
of the Na+/K+-ATPase by PLM reminiscent of a 
positive-cooperative effect. Once PLM-ATPase 
interaction has been initiated, by a mechanisms 
which remain to be investigated, PLM interacts 
fast and efficiently with ATPase molecules in the 
surroundings, which is facilitated by clustering of 
the Na+/K+-ATPase molecules observed by 
fluorescence microscopy and immunogold 
electron microscopy (37).  
 
PLM as a hydrophilic channel – The possibility of 
the formation of a hydrophilic channel by PLM for 
ions or taurine has been discussed in the literature 
(16-18). Visual analysis of the experimentally 
obtained PLM model shows that, no noticeable 
cavity exists,  and certainly not one that would 
accommodate a taurine molecule which has a 
diameter of >2.2Å (38,39) (also shown in figure 
3D for comparison). There are strong interactions 
between various residues occluding the central 
pore of the tetramer, thus we believe that any 
conformational change to an open pore would 
require major structural rearragements and 
disruption of inter-residue interactions, which are 
incompatible with the typical delicate balance 
between open-close conformations in voltage- or 
ligand-gated transmembrane channels. However, it 
has been shown that hyperpolarisation activates 
anion currents through PLM (40) and based on 
further experiments with embryonic kidney cells it 
has been hypothesised that PLM may facilitate 
osmolyte influx in renal tissue (18). Indeed, the 
clustering of four negative charges at the 
extracellular entrance would provide a binding site 
for the zwitterionic osmolyte taurine. In order to 
explore other possible packing models of PLM not 
encountered in the ATR-FTIR experiments, we 
performed an unconstrained MD conformational 
search. Among nine packing models, the lowest 
energy structure 4 shows a narrow central pore, 
which is only occluded by the Val34 residue. 
While structure 4 clearly shows a closed pore, the 
energy barrier for a conformational transition to an 
open pore might be overcome by voltage gating or 
binding of a ligand to the PLM molecule. We 
predict that mutation of Val34, e.g. Val34Gly, 
could abolish the gating behaviour and lead to a 
permanently open channel. This should be 
explored with further electrophysiology 
experiments using kidney cells as well as PLM 
transmembrane peptides in artificial lipid bilayer 
systems. 
In summary, the first experimental high resolution 
structural investigation of PLM gives credence to 
the hypothesis of a PLM tetramer as an inactive 
storage form that nevertheless allows very 
efficient regulation the Na+/K+-ATPase  in a 
process reminiscent of a positive-cooperative 
effect. An experimentally unconstrained modelling 
study identified another model of biological 
significance forming a potential closed 
conformation of a transmembrane channel. 
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FIGURE LEGENDS 
 
Figure 1: Infrared spectra for each peptide containing a 13C=18O label in the position indicated in the top 
right. The amide I area is displayed, while the insert shows the magnified amide I absorption band of the 
label. 
 
Figure 2: (A) Polar plot of the energies of structures obtained from MD simulation of PLM in dependence 
of the helix rotation angle φ changing clockwise from 0° to 360°. The distance from the centre indicates 
negative energy (E) in kJ/mol. Each individual structure is indicated by a triangle, while the clustered 
averages are shown as numbered circles. The arcs represent the movement of structures from their starting 
positions with respect to the helix rotation angle φ during the MD simulation. (B) The rotation of the helix 
tetramer defined as φ=0, Phe28 residues shown in wireframe. 
 
Figure 3: Resulting structure (structure 6) from MD simulation. (A) Showing the α-helical bundle in a 
lipid bilayer. (B) Spacefill rendering with labelled residues shown in black. (C) Positions of the Phe28 
residues in this model viewed from the top (the direction of the membrane normal). (D) Spacefill 
rendering of the model viewed from the top and a relative comparison to the size of a taurine molecule. 
All images were created using the VMD molecular rendering software (41). 
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Figure 4: (A) A surface rendering of the PLM tetramer model indicating residues in spacefill 
representation that would facilitate interaction between the PLM tetramer and the Na+/K+-ATPase. (B) 
The two stage model of the control of Na+/K+-ATPase by PLM tetramers. The PLM transmembrane 
helices are shaded in dark grey, while the Na+/K+-ATPase molecules are represented schematically in 
light grey. The view is in the direction of the cell membrane normal axis. Please note that the shape of the 
Na+/K+-ATPase is drawn arbitrarily and that no indication of the relative location of PLM and ATPase is 
implicated. 
 
Figure 5: (A) Polar plot of the energies of structures obtained from MD simulation of PLM in dependence 
of the helix rotation angle φ changing clockwise from 0° to 360°. The distance from the centre indicates 
negative energy (E) in kJ/mol. Each individual structure is indicated by a triangle, while the cluster 
average structures are shown as numbered circles. The arcs represent the movement of structures from 
their starting positions with respect to the helix rotation angle φ during the MD simulation. (B) Lowest 
energy structure 4 with pore-occluding residues Tyr27 and Val34 rendered in spacefill representation. 
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Table I: Experimentally determined orientations: rotational pitch angle ω, local tilt angle β and 
the derived angle of the carbonyl bond to the z-axis θ for all labels in the transmembrane domain 
– calculated from the SSID data. Standard errors are β±4° and ω±20°. 
 
Label β ω θ 
G20 8.9° 64° 40.2° 
L21 8.3° 119° 44.3° 
V22 4.9° 235° 36.8° 
I23 8.8° 327° 46.6° 
G25 8.7° 206° 32.0° 
I26 10.1° 302° 46.0° 
L27 6.2° 15° 43.4° 
G31 2.5° 213° 36.4° 
I32 7.3° 298° 43.4° 
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Table II: Comparison of rotational pitch angles from SSID with the structures produced from the 
MD search: ωexp  denotes the experimental rotational pitch angle, while ωmodel is the angle 
calculated from the computational model. The deviation between the MD simulated structures 
and the experimental data is also shown. This has been calculated using the equation 
( )∑ − 2modexp elωω  
Label ωexp ωmodel1 ωmodel2 ωmodel3 ωmodel4 ωmodel5 ωmodel6
G20 64° 57° 259° 322° 10° 203° 313° 
L21 119° 243° 341° 52° 71° 340° 27° 
V22 235° 334° 92° 160° 172° 31° 126° 
I23 327° 46° 200° 352° 301° 240° 304° 
G25 206° 347° 49° 23° 121° 147° 177° 
I26 302° 294° 355° 151° 9° 338° 315° 
L27 15° 352° 19° 10° 21° 54° 62° 
G31 213° 168° 108° 117° 85° 154° 156° 
I32 298° 271° 250° 279° 207° 262° 248° 
Deviation  1069 1054 879 794 880 669 
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